TLDR: The Artificial Intelligence (AI) in medical devices market is poised for record growth, projected to reach US$ 228.98 billion by 2031 with a CAGR of 34.7% from 2025. This expansion is driven by AI’s role in enhancing diagnostic precision, streamlining operations, and accelerating drug discovery, despite concerns regarding data bias and diagnostic accuracy.
The Artificial Intelligence (AI) in medical devices market is on the cusp of unprecedented expansion, with projections indicating a substantial surge in value over the coming years. Valued at US$ 21.50 billion in 2023, the market is expected to reach an impressive US$ 228.98 billion by 2031, demonstrating a robust Compound Annual Growth Rate (CAGR) of 34.7% from 2025 to 2032.
This remarkable growth is largely attributed to the increasing integration of AI-powered solutions across various facets of healthcare. AI is revolutionizing diagnostic precision, streamlining operational efficiencies, and significantly accelerating innovation in drug discovery and personalized treatment. The United States is anticipated to maintain its leadership in this market, bolstered by a strong AI research ecosystem and efficient regulatory approval processes for AI-enabled medical devices. Meanwhile, emerging economies like India and China are set to become the fastest-growing markets, with projected CAGRs of 17.6% and 17.1% respectively, fueled by digital healthcare initiatives and the pressing need to manage chronic diseases.
Key advancements include the deployment of AI-powered surgical robots that offer real-time guidance and advanced imaging interpretation, thereby enhancing precision and reducing recovery times. Healthcare providers currently dominate the end-user segment, accounting for 60% of the market share, as AI solutions improve diagnostic accuracy, automate administrative tasks, and facilitate personalized patient care. The success of AI in drug discovery has also attracted significant investment, with firms like Xaira securing substantial funding to advance these technologies. In the first half of 2024 alone, investments in AI healthcare startups exceeded USD 35 billion, with notable raises including Abridge’s USD 150 million for clinical documentation tools and Xaira Therapeutics’ USD 1 billion for AI-powered drug discovery.
Regulatory bodies are also adapting to this rapid technological shift. In May 2024, the MHRA launched ‘AI Airlock,’ a regulatory sandbox designed for the safe testing and deployment of AI medical devices. Innovations in diagnostic imaging, particularly the integration of deep learning algorithms, have achieved near radiologist-level accuracy in detecting conditions such as strokes and cancers, while also automating report generation and workflow prioritization. Major industry players are investing heavily, with Philips announcing a USD 150 million investment to expand production of AI-enabled ultrasound systems and Rad AI securing an additional $8 million in Series C funding for AI-driven diagnostic imaging solutions.
Despite the promising potential, the adoption and integration of AI in healthcare face challenges. The integration of AI with legacy systems remains a significant hurdle, especially in healthcare settings relying on outdated electronic health records. Furthermore, while 83% of doctors believe AI will be a net positive, a striking 70% express serious concerns about its use in the diagnostic process, fearing errors, bias, or misuse. Experts highlight the risk of systemic failure due to data bias and the ‘black box’ nature of many AI models, which can reinforce health disparities if trained on unrepresentative data and make it difficult for clinicians to verify conclusions.
Also Read:
- Global Growth Insights Identifies Top 21 AI Software Innovators Driving Market to $378 Billion by 2034
- Global AI Spending Projected to Reach $1.5 Trillion in 2025, Driven by Infrastructure and Product Integration
Overall, the AI in medical devices market is set for a period of transformative growth, driven by technological innovation and increasing investment, while also navigating critical considerations around ethical deployment and integration.
